X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
daratumumab (340) 340
multiple myeloma (286) 286
index medicus (247) 247
hematology (177) 177
oncology (170) 170
humans (158) 158
dexamethasone (155) 155
lenalidomide (132) 132
bortezomib (131) 131
open-label (103) 103
carfilzomib (96) 96
therapy (96) 96
daratumumab monotherapy (94) 94
multiple myeloma - drug therapy (90) 90
monoclonal antibodies (88) 88
elotuzumab (87) 87
cd38 (75) 75
immunotherapy (67) 67
patients (64) 64
antibodies, monoclonal - therapeutic use (58) 58
low-dose dexamethasone (57) 57
survival (57) 57
pomalidomide (54) 54
care and treatment (49) 49
stem-cell transplantation (46) 46
antineoplastic combined chemotherapy protocols - therapeutic use (45) 45
female (45) 45
male (45) 45
cancer (43) 43
middle aged (43) 43
aged (42) 42
multiple-myeloma (41) 41
antineoplastic agents - therapeutic use (38) 38
multiple myeloma - therapy (37) 37
clinical trials (36) 36
combination (36) 36
monotherapy (35) 35
proteasome inhibitors (35) 35
pharmacology & pharmacy (34) 34
analysis (33) 33
antitumor-activity (33) 33
drug therapy (33) 33
ixazomib (33) 33
minimal residual disease (33) 33
transplantation (33) 33
adult (32) 32
cd38 antigen (31) 31
immunology (31) 31
multiple myeloma - pathology (31) 31
targeting cd38 (31) 31
interference (30) 30
multiple myeloma - immunology (28) 28
myeloma (28) 28
antibody daratumumab (27) 27
medicine & public health (27) 27
treatment outcome (27) 27
efficacy (25) 25
lenalidomide plus dexamethasone (25) 25
multicenter (25) 25
thalidomide - analogs & derivatives (25) 25
abridged index medicus (24) 24
monoclonal antibody (24) 24
review (24) 24
cytotoxicity (23) 23
relapse (23) 23
stem cells (23) 23
antibodies, monoclonal - administration & dosage (22) 22
chemotherapy (22) 22
diseases (22) 22
immunomodulation (22) 22
medical research (22) 22
animals (21) 21
cells (21) 21
expression (21) 21
panobinostat (21) 21
aged, 80 and over (20) 20
antibodies, monoclonal - adverse effects (20) 20
criteria (20) 20
multiple myeloma - mortality (20) 20
research (20) 20
leukemia (19) 19
medicine, general & internal (19) 19
toxicity (19) 19
antibodies (18) 18
biological products (18) 18
hemic and lymphatic diseases (18) 18
multiple myeloma - diagnosis (18) 18
recurrence (18) 18
refractory materials (18) 18
refractory multiple-myeloma (18) 18
antibody (17) 17
article (17) 17
bone-marrow (17) 17
diagnosis (17) 17
phase-2 (17) 17
stem cell transplantation (17) 17
thalidomide (17) 17
development and progression (16) 16
health aspects (16) 16
immunotherapy - methods (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4792 - 4792
Abstract Background: Lenalidomide and low-dose dexamethasone (Rd)-based therapies are widely used in the USA, while both Rd and bortezomib, melphalan, and... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 3551 - 3551
Abstract Introduction: Daratumumab-bortezomib-melphalan-prednisone (D-VMP) is a novel treatment regimen for newly diagnosed multiple myeloma patients who are... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5651 - 5651
Abstract Introduction Multiple myeloma (MM) is considered an incurable disease. However, during the last years the survival has improved, partly due to the... 
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2019, Volume 187, Issue 3, pp. 275 - 276
Journal Article
Haematologica, ISSN 0390-6078, 11/2018, Volume 103, Issue 12, pp. 2088 - 2096
In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in... 
CRITERIA | ANTIBODY DARATUMUMAB | HEMATOLOGY
Journal Article
Internal Medicine, ISSN 0918-2918, 2019
We report a case of disseminated cryptococcosis in a patient with multiple myeloma (MM) during treatment with daratumumab, lenalidomide, and dexamethasone... 
disseminated cryptococcosis | daratumumab | lymphopenia
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2244 - 2244
Abstract Introduction Compliance with Multiple Myeloma (MM) recommendations regarding diagnosis and treatment is highly variable worldwide, outside clinical... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. e20049 - e20049
Journal Article
Journal of Nuclear Medicine, ISSN 0161-5505, 02/2018, Volume 59, Issue 2, pp. 216 - 222
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 09/2018, Volume 18, pp. S76 - S79
Journal Article
Leukemia, ISSN 0887-6924, 12/2017
During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved treatment... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2018, Volume 36, Issue 8, pp. 728 - 734
PurposeIn the ASPIRE study of carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide plus dexamethasone (Rd) in patients with relapsed or... 
DARATUMUMAB | TRIALS | THERAPY | ONCOLOGY | PROGRESSION-FREE SURVIVAL | FOLLOW-UP | ENDEAVOR | OPEN-LABEL | BORTEZOMIB | ASPIRE | Index Medicus
Journal Article
The American Journal of the Medical Sciences, ISSN 0002-9629, 04/2019, Volume 357, Issue 4, pp. e11 - e12
Journal Article
Immunology Letters, ISSN 0165-2478, 01/2019, Volume 205, pp. 71 - 77
The fist in class CD38-targeting antibody, daratumumab, is currently approved as single agent and in combination with standards of care for the treatment of... 
Monoclonal antibodies | CD38 | Adenosine | Daratumumab | Multiple myeloma
Journal Article
Journal of Oncology Practice, ISSN 1554-7477, 07/2018, Volume 14, Issue 7, pp. 425 - 426
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 2018, Volume 41, Issue 12, pp. 788 - 789
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2018, Volume 181, Issue 4, pp. 447 - 459
Summary Multiple myeloma (MM) is the second most common haematological malignancy after non‐Hodgkin lymphoma. Despite the improvement in outcomes over the last... 
multiple myeloma | Daratumumab | Elotuzumab | monoclonal antibodies | OPEN-LABEL | PHASE-2 | BORTEZOMIB | COMBINATION | THERAPY | HUMAN CD38 | LENALIDOMIDE | DARATUMUMAB MONOTHERAPY | HEMATOLOGY | LOW-DOSE DEXAMETHASONE | Monoclonal antibodies | Usage | Drug therapy | Multiple myeloma | Medical research | Hematology | Immunomodulation | Medical treatment | Medical services | Clinical trials | Malignancy | Lymphoma | Patients | Proteasome inhibitors
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.